Opendata, web and dolomites
H2020 projects about "checkpoint"
The page lists 51 projects related to the topic "checkpoint".
| # | |||
|---|---|---|---|
| 1 | GermAge | The aging germ cell – biological pathways, risk factors and mechanisms underlying an increasing medical and socio-economic problem | 2015 |
| 2 | ApoptoMDS | Hematopoietic stem cell Apoptosis in bone marrow failure and MyeloDysplastic Syndromes: Friend or foe? | 2015 |
| 3 | SAC_EarlyEmbryo | SAC robustness in the transition from meiosis to mitosis | 2016 |
| 4 | CSC-IS | Development of a more effective and safer therapeutic antibody for cancer treatment with a dual mechanism of action to eliminate CSCs and reactivate the tumour’s immune system. | 2015 |
| 5 | Organoid | Dissecting microbiome and immune interactions in human intestinal (cancer) organoids | 2015 |
| 6 | iGEMMdev | Development and Characterisation of New Immunogenic GEMMs of Lung Cancer | 2017 |
| 7 | ENVERESP | Crosstalk between nuclear envelope and DNA Damage Response: Role of nucleoporin TPR in the maintenance of genomic integrity | 2016 |
| 8 | PeptiCrad | Personalized oncolytic vaccines for cancer immunotherapy | 2016 |
| 9 | CHEMCHECK | CHECKPOINTS IN CHECK: Novel Chemical Toolbox for Local Cancer Immunotherapy | 2016 |
| 10 | CODECHECK | CRACKING THE CODE BEHIND MITOTIC FIDELITY: the roles of tubulin post-translational modifications and a chromosome separation checkpoint | 2016 |
| 11 | TNT-TUMORS | Therapeutic approaches to enhance innate immunity against Tumors | 2016 |
| 12 | BITCAT | Blocking Inhibition of T-cell Co-stimulation for Anti-tumour Therapy | 2017 |
| 13 | HYPOXIMMUNO | Tackling the Achilles Heel of Immunotherapy: Validating imaging biomarkers and targeting the immunological niche of tumour hypoxia | 2016 |
| 14 | Nod2Root | Keeping nodules in check: Interplay of rhizobial and host factors controlling nodule morphogenesis and identity in legume plants. | 2017 |
| 15 | IC_IL_EC_2017 | Investigating the effects of immunogenic chemoradiation in shaping the immune landscape of esophageal cancers | 2018 |
| 16 | TIGITtherapy | TIGIT therapy for cancer treatment | 2017 |
| 17 | ImmuneCheckpointsAD | Immune checkpoint blockade for fighting Alzheimer’s disease | 2017 |
| 18 | SENSIT | Sensitivity of human tumors to T cell attack | 2017 |
| 19 | ORI NUMBER | Unravelling the effect of origin number on the success of genome replication | 2017 |
| 20 | OMVCRC | Engineered bacterial Outer Membrane Vesicles (OMVs) for colorectal cancer immunotherapy | 2018 |
| 21 | IMMUNOMARK | Omics integration for precision cancer immunotherapy | 2018 |
| 22 | BREFMC2017 | Deciphering the function(s) of the C-type lectin DCIR/CLEC4A in tuberculosis | 2018 |
| 23 | DNAcheck | Mechanistic analysis of DNA damage signaling and bypass upon replication of damaged DNA template in human cells. | 2018 |
| 24 | UTILIUM | Unraveling The Immune Landscape In Uveal Melanoma | 2018 |
| 25 | MATURE-NK | MAnufacturing of TUmour-REactive Natural Killer cells | 2018 |
| 26 | HOPE | Host Protective Engineering of Cancer Immunity by Targeting the Intracellular Immune Checkpoint NR2F6 | 2018 |
| 27 | PaSION | A longitudinal assessment of treatment experience, symptoms and potential associations with biomarkers in cancer patients undergoing immune checkpoint inhibitor therapy | 2018 |
| 28 | PML-THERAPY | HARNESSING PML NUCLEAR BODIES FOR LEUKAEMIA THERAPY | 2019 |
| 29 | CL-IO | Commercial feasibility of non-pathogenic Clostridium-Mediated Cancer Immunotherapy: leveraging the presence of tumour hypoxia & necrosis | 2018 |
| 30 | EPIC | Enabling Precision Immuno-oncology in Colorectal cancer | 2018 |
| 31 | STIMUNO | Searching for novel strategies improving cancer immunotherapy | 2019 |
| 32 | NextGen IO | Exploiting the hypoxia response in T cells for Next-Generation Immuno-Oncology | 2019 |
| 33 | PanCaVax | Personalised Pancreatic Cancer Vaccination Therapy derived from Autologous Tumor Cells and Neoantigens | 2018 |
| 34 | ONCOBIOME | Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response. | 2019 |
| 35 | FTHPC | Fault Tolerant High Performance Computing | 2019 |
| 36 | UCTIL | Urban Chemical Threat Location and Identification | 2019 |
| 37 | Need2immune | Personalized liposomal cancer vaccines within days by rapid formulation screening | 2019 |
| 38 | CheckBacZ | Checkpoints in the bacterial cell cycle: role of the cytokinetic Z-ring and implications for antibiotic resistance | 2020 |
| 39 | SingCelCD | Single Cell approaches for the study of oncogenic processes during coeliac disease. | 2019 |
| 40 | MIMIC | Deciphering how microbiota modulate anti-tumor immune responses in checkpoint therapy | 2020 |
| 41 | UNPACK PD-L1 | Molecular mechanism and inhibition of extracellular vesicle-mediated PD-L1 release in melanoma cells | 2020 |
| 42 | FRAME | FRAME - tumor genome-based personalized anti-cancer vaccines off-the-shelf | 2019 |
| 43 | Cenya | Ex vivo cell labelling for in vivo imaging applied to cell therapeutics | 2019 |
| 44 | Synthetic T-rEX | A synthetic biology approach for T cell exhaustion | 2020 |
| 45 | RARITY | RAtional design of canceR ImmunoTherapY: one size does not fit all | 2019 |
| 46 | STI-001 | Turn Cancer Immunotherapy Effective in Most Patients | 2019 |
| 47 | TESTIMONY | Tumor Endothelial Cells: Gatekeepers Of Anti-Tumor Immunity | 2020 |
| 48 | NetriCan | Characterization of the role of netrin-1 in the regulation of the Epithelial-to-Mesenchymal Transition during tumor progression. | 2020 |
| 49 | GlioTarget | Inflaming the microenvironment of glioblastoma tumors by ADAR1 inhibition: a two-hit approach for the treatment of brain cancer. | 2021 |
| 50 | Irrev Fork Arrest | Deciphering the mechanism of irreversible replication fork arrest | 2020 |
| 51 | RCC_Evo | Modelling the Predictability and Repeatability of Tumour Evolution in Clear Cell Renal Cell Cancer | 2020 |